Compare BXMX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXMX | NVAX |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | BXMX | NVAX |
|---|---|---|
| Price | $13.26 | $8.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 105.9K | ★ 3.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.14 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $12.00 | $5.80 |
| 52 Week High | $15.00 | $11.85 |
| Indicator | BXMX | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 29.96 | 44.12 |
| Support Level | N/A | $8.09 |
| Resistance Level | $14.64 | $8.45 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 0.65 | 39.80 |
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.